Pharsight

MEDIMMUNE PATENTS FACING OPPOSITIONS

Top patents of MEDIMMUNE facing oppositions at the European Patent Office (EPO).

Patent Number Grant Date Patent Title Expected Expiration Date Facing Oppositions Activity Alert
EP3218406B1 24 Mar, 2021 Binding molecules specific for cd73 and uses thereof Nov, 2035 2
EP2997036B1 03 Mar, 2021 Purification of recombinantly produced polypeptides NA 2
EP3157629B1 05 Oct, 2022 Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy Jun, 2035 1
EP3329018B1 31 Mar, 2021 Il-6 antagonists for use in treating hepcidin-mediated disorders Jul, 2036 1
EP1942939B2 30 May, 2018 Interleukin-13 antibody composition NA 1
EP2935268B2 22 Nov, 2017 Pyrrolobenzodiazepines and conjugates thereof NA 1
EP2624859B1 01 Mar, 2017 Factor ii alone or in combination with further factors for treatment of impaired haemostasis associated with dilutional coagulopathy Sep, 2031 1